Virtual Library
Start Your Search
H. He
Author of
-
+
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
-
+
P043 - Cost-Effectiveness Analysis of Different Sequences of Osimertinib Administration for EGFR-Mutated Non-Small-Cell Lung Cancer (ID 35)
00:00 - 00:00 | Author(s): H. He
- Abstract
Background:
Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is clinically effective as a first-line and second-line therapy in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). Use of this treatment is limited by high costs. Here, we conducted a cost-effectiveness analysis of different sequences of osimertinib administration in China and the United States.
Method:
We established Markov models based on data from the FLAURA and AURA3 trials, which included patients with EGFR mutation-positive advanced NSCLC. The cost-effectiveness analysis compared first-line osimertinib to first-generation EGFR-TKIs or second-line osimertinib after the failure of first-generation EGFR-TKIs. The analysis also considered different payment modalities available in China. Additionally, we performed 1-way sensitivity and probability sensitivity analyses with a willingness-to-pay threshold (WTP) of 3